Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

42.14
-0.4300-1.01%
Volume:314.50K
Turnover:13.28M
Market Cap:1.36B
PE:-14.10
High:43.50
Open:43.33
Low:41.78
Close:42.57
52wk High:50.16
52wk Low:13.36
Shares:32.26M
Float Shares:21.62M
Volume Ratio:1.33
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9880
EPS(LYR):-3.1329
ROE:-50.00%
ROA:-29.98%
PB:4.09
PE(LYR):-13.45

Loading ...

LB Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 27

HC Wainwright Initiates Coverage on LB Pharmaceuticals With Buy Rating, $45 Price Target

MT Newswires Live
·
Apr 27

LB Pharmaceuticals initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Apr 27

LB Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 24

Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (LBRX) and West Pharmaceutical Services (WST)

TIPRANKS
·
Apr 24

Piper Sandler Reaffirms Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)

TIPRANKS
·
Apr 23

LB Pharma publishes positive Phase 2 LB-102 schizophrenia trial results in JAMA Psychiatry

Reuters
·
Apr 23

Lb Pharmaceuticals Announces Publication in Jama Psychiatry of Results From Phase 2 Nova-1 Trial of Lb-102 in Schizophrenia

THOMSON REUTERS
·
Apr 23

LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know

TIPRANKS
·
Apr 19

LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM

TIPRANKS
·
Apr 15

LB Pharmaceuticals Initiated at Buy by Craig-Hallum

Dow Jones
·
Apr 11

LB Pharmaceuticals initiated with a Buy at Craig-Hallum

TIPRANKS
·
Apr 10

LB Pharmaceuticals CEO to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 10

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
Apr 10

LB Pharmaceuticals files to sell 4.78M shares of common stock for holders

TIPRANKS
·
Apr 07

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

Reuters
·
Mar 27

LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.

Benzinga Earnings
·
Mar 27

LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)

TIPRANKS
·
Mar 27

LB Pharmaceuticals FY2025 net loss narrows 60.06% to $25 million; research and development expenses fall 67.38% to $17 million

Reuters
·
Mar 27

Lb Pharmaceuticals Inc - Q4 Net Loss per Share $0.45

THOMSON REUTERS
·
Mar 27